Source comparison
MK-677 Discontinuation: Side Effect Comparison
The decision to stop taking MK-677 should be informed by an understanding of what rebound effects are physiologically normal versus what signals a more concerning disruption. The table below compares abrupt cessation, structured taper, and extended low-dose pr
This comparison does not assign a generated winner or score.
- The decision to stop taking MK-677 should be informed by an understanding of what rebound effects are physiologically normal versus what signals a more concerning disruption. The table below compares abrupt cessation, structured taper, and extended low-dose protocols across the most commonly reported discontinuation variables.
- Abrupt cessation after 12+ weeks
- Severe—constant hunger, evening cravings, 20–30% increase in caloric intake
- 7–10 days—reduced REM, frequent waking, delayed sleep onset
- 2–5 lbs loss—rapid extracellular fluid shift
- 14–18 days
- Highest rebound symptom intensity; cortisol normalization delayed; not recommended for doses >20mg daily
- 10–14 day taper (25% reduction every 3 days)
- Moderate—noticeable increase but manageable with structured meal timing
- 4–6 days—mild fragmentation, normal by day 7
- 1–3 lbs loss—gradual fluid adjustment
- 16–21 days
- Optimal risk-benefit ratio; allows receptor downregulation in parallel with dose reduction; standard protocol
- Extended low-dose maintenance (5–10mg every 48–72h)
- Minimal—hunger normalizes gradually over 2–3 weeks
- 2–4 days—transient only
- <1 lb—negligible fluid shift
- 21–28 days
- Longest normalization timeline; useful for users with history of severe rebound; not suitable for true discontinuation